![Tom Schwarz](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Tom Schwarz
Presidente presso
20Med Therapeutics BV
Profilo
Tom Schwarz is the founder of LSP Management Group BV, Erasmus Medical Center (Private Equity), and Seed Fund Management BV.
LSP Management Group BV was founded in 1998, Erasmus Medical Center (Private Equity) was founded in 2007, and Seed Fund Management BV was founded in 2009.
Dr. Schwarz's current jobs include Chairman-Supervisory Board at 20Med Therapeutics BV, Director-Supervisory Board at Corgo NV, Member-Supervisory Board at Regenesance BV, and General Partner at Innovation Industries Management BV.
Dr. Schwarz's former jobs include Chairman at AIMM Therapeutics BV, Director at Micronit Microfluidics BV, and Partner at Twente Technology Fund Management BV.
Dr. Schwarz received an undergraduate degree from the University of Utrecht.
Posizioni attive di Tom Schwarz
| Società | Posizione | Inizio |
|---|---|---|
Corgo NV
 Corgo NV Miscellaneous Commercial ServicesCommercial Services Specializes in corporate consulting services | Direttore/Membro del Consiglio | 05/05/2009 |
Regenesance BV
 Regenesance BV Drugstore ChainsRetail Trade Develops drugs for the treatment of neurodegenerative and immune mediated disorders | Direttore/Membro del Consiglio | 01/02/2011 |
20Med Therapeutics BV
 20Med Therapeutics BV BiotechnologyHealth Technology Operates as a biomedical company | Presidente | - |
Innovation Industries Management BV
 Innovation Industries Management BV Investment ManagersFinance Innovation Industries Management invests in companies located in Netherlands. The firm targets companies operating in the fields of industrial tech, med-tech and agri-tech industries. It provides for early and growth stage capital requirements with an investment size up to EUR 150 million. | Investitore di Private Equity | 01/01/2016 |
Precedenti posizioni note di Tom Schwarz
| Società | Posizione | Fine |
|---|---|---|
Erasmus Medical Center (Private Equity)
 Erasmus Medical Center (Private Equity) Investment ManagersFinance The Erasmus Fund's investment objective is to provide capital to support biomedical entrepreneurial activity at the Erasmus MC as well as in the Rotterdam area. The fund's investment strategy targets pre-seed, seed and early-stage firms and university spin-outs that are developing commercially promising technologies and products. They focus on the life science sector, including biotechnology, biomedical, pharmaceuticals, information technology and other high technology opportunities. The fund investment size can reach up to EUR 20 million. The fund's investment team works closely with the Erasmus MC technology transfer office which facilitates the transfer to the private sector of developing technologies. The close cooperation also provides emerging technology firms and university researchers with seed funding opportunities with other venture capitalists, and focused financial and technical support. Investments have been made in the development of biochips for acute myeloid leukemia, brain tumors and myeloma, diagnostic and therapeutic tools for the treatment of vulnerable plaques, medical diagnostic instruments in the field of micro-organism identification and skin composition analysis, and new drug targets for a wide array of bone diseases, including osteoporosis, osteoarthritis, and bone metastasis. | Fondatore | 01/01/2016 |
Seed Fund Management BV
 Seed Fund Management BV Investment ManagersFinance Functions as an alternative investment manager | Fondatore | 01/01/2016 |
Twente Technology Fund Management BV
 Twente Technology Fund Management BV Investment ManagersFinance Acts as an alternative investment manager | Investitore di Private Equity | 01/01/2016 |
AIMM Therapeutics BV
 AIMM Therapeutics BV Pharmaceuticals: MajorHealth Technology Develops therapeutic antibodies for the treatment of cancer and infectious diseases | Presidente | - |
Micronit Microfluidics BV
 Micronit Microfluidics BV SemiconductorsElectronic Technology Designs, develops, and manufactures glass-based lab-on-a-chip products | Direttore/Membro del Consiglio | - |
Formazione di Tom Schwarz
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
14
Relazioni di 1° grado
11
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 11 |
|---|---|
LSP Management Group BV
 LSP Management Group BV Investment ManagersFinance EQT Life Sciences invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, medical devices, diagnostics and healthtech sectors. It provides financing for early and later stage capital requirements with an investment size of EUR 10 – 60 million. | Finance |
University of Utrecht
 University of Utrecht Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Corgo NV
Corgo NV Miscellaneous Commercial ServicesCommercial Services Specializes in corporate consulting services | Commercial Services |
Erasmus Medical Center (Private Equity)
Erasmus Medical Center (Private Equity) Investment ManagersFinance The Erasmus Fund's investment objective is to provide capital to support biomedical entrepreneurial activity at the Erasmus MC as well as in the Rotterdam area. The fund's investment strategy targets pre-seed, seed and early-stage firms and university spin-outs that are developing commercially promising technologies and products. They focus on the life science sector, including biotechnology, biomedical, pharmaceuticals, information technology and other high technology opportunities. The fund investment size can reach up to EUR 20 million. The fund's investment team works closely with the Erasmus MC technology transfer office which facilitates the transfer to the private sector of developing technologies. The close cooperation also provides emerging technology firms and university researchers with seed funding opportunities with other venture capitalists, and focused financial and technical support. Investments have been made in the development of biochips for acute myeloid leukemia, brain tumors and myeloma, diagnostic and therapeutic tools for the treatment of vulnerable plaques, medical diagnostic instruments in the field of micro-organism identification and skin composition analysis, and new drug targets for a wide array of bone diseases, including osteoporosis, osteoarthritis, and bone metastasis. | Finance |
Micronit Microfluidics BV
Micronit Microfluidics BV SemiconductorsElectronic Technology Designs, develops, and manufactures glass-based lab-on-a-chip products | Electronic Technology |
Twente Technology Fund Management BV
Twente Technology Fund Management BV Investment ManagersFinance Acts as an alternative investment manager | Finance |
Regenesance BV
Regenesance BV Drugstore ChainsRetail Trade Develops drugs for the treatment of neurodegenerative and immune mediated disorders | Retail Trade |
Seed Fund Management BV
Seed Fund Management BV Investment ManagersFinance Functions as an alternative investment manager | Finance |
AIMM Therapeutics BV
AIMM Therapeutics BV Pharmaceuticals: MajorHealth Technology Develops therapeutic antibodies for the treatment of cancer and infectious diseases | Health Technology |
20Med Therapeutics BV
20Med Therapeutics BV BiotechnologyHealth Technology Operates as a biomedical company | Health Technology |
Innovation Industries Management BV
Innovation Industries Management BV Investment ManagersFinance Innovation Industries Management invests in companies located in Netherlands. The firm targets companies operating in the fields of industrial tech, med-tech and agri-tech industries. It provides for early and growth stage capital requirements with an investment size up to EUR 150 million. | Finance |
